Practice Fusion to Present Real World Data on the Treatment of Diabetes and COPD at the ISPOR 22nd Annual International Meeting
San Francisco, CA, May 16, 2017 – Practice Fusion, Inc., the leading cloud-based electronic health record (EHR) platform, today announced that it will present new real world data on the treatment of type II diabetes (T2D) and chronic obstructive pulmonary disease (COPD) at the 22nd annual meeting for the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) in Boston, May 20-24, 2017. This is Practice Fusion’s first series of poster presentations at the industry leading conference since announcing its real world evidence capabilities at the annual conference last year.
During the conference, principal data analysts from Practice Fusion’s Life Sciences Team will present the scientific posters described below, all of which leveraged real world data from Practice Fusion’s certified, statistically de-identified clinical database consisting of over 38 million de-identified patient records.
- Real World Effectiveness of Dulaglutide Among Patients with Type 2 Diabetes
This retrospective study assessed the change in HbA1c among patients with uncontrolled T2D initiating treatment with dulaglutide. The results demonstrated that, in real-world settings, patients with uncontrolled T2D demonstrated an improvement in their glycemic control within six months of initiating treatment with dulaglutide.
- Characteristics Associated with the Choice of First Injectable Therapy Among US Patients with Type 2 DiabetesPoster PDB93
This retrospective study observed characteristics associated with the choice of first injectable therapies among patients with T2D. First injectable therapies include glucagon-like peptide-1 receptor agonist (GLP-1-RA) or basal insulin (BI). In real world settings, the study found that key predictors that may influence the choice of a GLP-1-RA as first injectable were a higher BMI and obesity; and for initiating BI were worse glycemic control, older age, and higher disease burden.
- Comparative Analysis of Nebulized Arformoterol vs Inhaled Long-Acting Beta-Agonists for COPD: Rescue Medication Use and Medical Outcomes
This retrospective study compared rescue medication use and outcomes among COPD patients treated with arformoterol veruan inhaled long acting beta-2 agonists (LABA). In real world settings, the study found that arformoterol treatment was associated with lower rescue medication use and physician office visits when compared to an inhaled LABA treatment.
The posters are on display during the ISPOR Poster Presentations Session III Tuesday, May 23 from 8:30 a.m. to 2:00 p.m. EST with an author led discussion at 1:00 p.m. EST.
Answering challenging research questions with real world evidence
“The data from Practice Fusion’s de-identified clinical research database provides researchers with the ability to pull large and representative number of de-identified patient records for study cohorts” said Lee Kallenbach, PhD, MPH, acting as Director of Research and Principal Data Analyst at Practice Fusion for the T2D abstracts. “What was unique about the research we performed for the abstracts on T2D treatments is the availability of HbA1c lab results and most importantly, the ability to code the amount dispensed for variable dose GLP-1-RA click pens based on available prescription sig data. Obtaining this kind of real world data outside of a controlled clinical setting with a large sample size and in a timely manner in research is unheard of.”
The same holds true for the COPD abstract. “We were able to pull longitudinal records from a large nationally representative sample with relevant clinical data (e.g., eosinophils) and with additional diagnostic granularity from SNOMED coding,” said Joe Vasey, PhD, acting as Director of Biostatistics and Principal Data Analyst at Practice Fusion. “Research similar to this would take years to amass this amount of rich clinical data from disparate systems and we were able to do it in less than a year with statistical significance.”
“Practice Fusion’s presentations at this year’s ISPOR conference is just one example of how Practice Fusion is adding to the body of evidence to some of the most challenging research questions,” said Tom Langan, CEO at Practice Fusion. “We have many more research publications on the horizon as industry leaders are recognizing the capabilities of our de-identified clinical research database, our cloud-based platform, and most importantly, the incredible expertise of our world-class team.”
About Practice Fusion
Practice Fusion is the #1 cloud-based electronic health record (EHR) platform for doctors and patients in the U.S., with a mission of connecting doctors, patients and data to drive better health and save lives. By facilitating over five million patient visits a month with more than 600 connected partners, Practice Fusion helps coordinate care within the largest healthcare ecosystem in the U.S. As the most widely used cloud-based ambulatory EHR, Practice Fusion is helping to reshape the future of healthcare.
Rob Purvis, Senior Director of Marketing
Learn more about Practice Fusion’s Real World Evidence Solutions
Contact Joe Priest, acting as Vice President of Real World Evidence: